Effects of chlordiazepoxide, diazepam and oxazepam on the antitumor activity and acute toxicity of cyclophosphamide and the level of its active metabolites in the plasma were investigated in mice. Cyclophosphamide was administered 24 h after the final injection of chlordiazepoxide, diazepam or oxazepam (100 mg/kg/d for 3 d, i.p.). Pretreatment with these drugs increased the acute toxicity of cyclophosphamide (300 or 450 mg/kg, i.p.), whereas drugs had no effect on the antitumor activity of cyclophosphamide (100 mg/kg, i.p.) against Ehrlich solid carcinoma. A high level of active metabolites of cyclophosphamide in the plasma after the administration of cyclophosphamide (300 or 450 mg/kg, i.p.) was observed in chlordiazepoxide-, diazepam- or oxazepam-treated mice. On the other hand, chlordiazepoxide, diazepam or oxazepam enhanced significantly the activity of cyclophosphamide oxidase in hepatic microsomes. It is concluded that potentiation of the acute toxicity at a high dose of cyclophosphamide by chlordiazepoxide, diazepam and oxazepam is due to an induction of microsomal drug-metabolizing enzyme which are responsible for the in vivo activation of cyclophosphamide.

Download full-text PDF

Source
http://dx.doi.org/10.1248/bpb1978.6.767DOI Listing

Publication Analysis

Top Keywords

chlordiazepoxide diazepam
20
diazepam oxazepam
20
antitumor activity
12
level active
12
active metabolites
12
acute toxicity
12
cyclophosphamide
11
effects chlordiazepoxide
8
oxazepam antitumor
8
metabolites cyclophosphamide
8

Similar Publications

Introduction: Alcohol withdrawal syndrome (AWS) is a common condition prompting emergency department (ED) presentation. However, there are limited recent, large-scale, robust data available on the incidence, admission, and medical treatment of AWS in the ED.

Methods: This was a retrospective cohort study of ED presentations for AWS from January 1, 2016, to December 31, 2023, using Epic Cosmos.

View Article and Find Full Text PDF

Purpose: On November 28, 2023, the U.S. FDA issued a Drug Safety Communication, warning that antiseizure medications (ASMs) levetiracetam and clobazam can cause a rare but serious reaction, drug reaction with eosinophilia and systemic symptoms (DRESS).

View Article and Find Full Text PDF

Nonsedating anxiolytics.

Pharmacol Biochem Behav

December 2024

RespireRx Pharmaceuticals Inc., Glen Rock, NJ, USA.

Anxiety disorders are the most prevalent psychiatric pathology with substantial cost to society, but the existing treatments are often inadequate. This has rekindled the interest in the GABA-receptor (GABAR) positive allosteric modulator (PAM) compounds, which have a long history in treatment of anxiety beginning with diazepam, chlordiazepoxide, and alprazolam. While the GABAR PAMs possess remarkable anxiolytic efficacy, they have fallen out of favor due to a host of adverse effects including sedation, motor impairment, addictive potential and tolerance development.

View Article and Find Full Text PDF

Greener analysis of eleven basic drugs in blood and urine using carbowax 20M based biofluid sampler (BFS) device.

J Chromatogr B Analyt Technol Biomed Life Sci

October 2024

Institute of Forensic Science & Criminology, Panjab University, Chandigarh 160014, India. Electronic address:

Article Synopsis
  • * The BFS allows for the collection of biological samples without dilution or pre-treatment, with analytes successfully back-extracted for analysis using gas chromatography-mass spectrometry (GC-MS).
  • * The method demonstrated good precision and recovery rates, making it suitable for forensic toxicology applications, while also being evaluated for its environmentally friendly characteristics.
View Article and Find Full Text PDF

For the past 60 years, benzodiazepines such as chlordiazepoxide, diazepam, and alprazolam have been used as pharmaceutical medications for the treatment of myriad conditions including anxiety, seizures, and insomnia. In more recent years, novel benzodiazepine derivatives have emerged as illicit substances in powders and counterfeit tablets on the illicit drug market. In 2016, bromazolam, a brominated derivative of alprazolam, emerged on the illicit drug market in Europe, but the substance was not reported in the USA until 2019-2020.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!